ED50 values (milligram/kilogram, subcutaneously; 95% confidence limits are in parentheses) of JNJ-37822681 and seven reference compounds for D2 receptor occupancy and inhibition of stimulant-induced behavior 1 h after subcutaneous administration
| Test Compound | ED50 | ||||
|---|---|---|---|---|---|
| D2 Occupancy In Vivo | Inhibition of Apomorphine-Induced Stereotypy | Blockade of Apomorphine-Induced Stereotypy | Inhibition of d-Amphetamine Hyperlocomotion | Inhibition of Phencyclidine Hyperlocomotion | |
| JNJ-37822681 | 0.39 (0.31–0.49) | 0.19 (0.14–0.26) | 8.1 (6.0–11) | 1.0 (0.68–1.5) | 4.7 (3.3–6.6) |
| Aripiprazole | 0.58 (0.44–0.76) | 0.59 (0.43–0.80) | 5.4 (4.0–7.3) | 0.26 (0.16–0.41) | 3.6 (2.0–6.5) |
| Clozapine | 8.5 (6.2–12) | 16 (12–22) | >160 | 2.0 (1.5–2.8) | 3.6 (2.4–5.3) |
| Haloperidol | 0.018 (0.014–0.022) | 0.028 (0.023–0.035) | 0.26 (0.19–0.35) | 0.064 (0.048–0.087) | 0.112 (0.075–0.17) |
| Olanzapine | 0.15 (0.13–0.17) | 0.22 (0.15–0.33) | 7.1 (5.2–9.6) | 1.0 (0.75–1.4) | 1.0 (0.68–1.5) |
| Quetiapine | 13 (9.6–17) | 12 (8.3–18) | >160 | 4.7 (3.1–7.0) | 14 (12–18) |
| Risperidone | 0.11 (0.09–0.14) | 0.26 (0.16–0.40) | 2.7 (2.0–3.6) | 0.44 (0.36–0.55) | 0.51 (0.32–0.83) |
| Ziprasidone | 0.24 (0.18–0.36) | 0.28 (0.20–0.38) | 4.7 (3.4–6.3) | 0.29 (0.19–0.35) | 1.2 (0.78–1.8) |